Ashish Singh
@todrashish
Followers
1K
Following
3K
Media
40
Statuses
857
Professor, Medical Oncology, Christian Medical College Vellore India
Vellore
Joined April 2016
amazing, TMCi should be a standard treatment in every suitable patient. not only in LMIC . .
Thrilled to see our work on oral metronomic chemotherapy featured by Prof. David Kerr (@UniofOxford) on MEDSCAPE !. 📰 “The Global Applicability of Oral Metronomic Chemotherapy”.🔗 Pushing the boundaries to equitable cancer care!.#GlobalOnco @TMC_Varanasi
0
3
10
Our experience in very advanced LAHNSCC . there is probably a role of intensified local treatment in exceptional responders. we need prospective randomised trials @TataMemorial @CancerGridIndia @VanitaNoronha @sarbani30 @drmpk91 @jtgeorgy @CancerCare.
0
2
9
RT @drmpk91: 💸 Why Financial Toxicity (#FinTox) matters in cancer care.Key insights from Dr @fumikochino’s excellent plenary at #MASCC25 :….
0
12
0
RT @jtgeorgy: Congrats @drmpk91 for presenting your Mind & Money study from our medonc dept @OffCMCVellore as oral at #MASCC25! these are m….
0
2
0
RT @ajoyojohn: Congratulations @drmpk91 for your eye opening work! Financial distress is a known problem for Indian cancer patients, but it….
0
4
0
RT @drmpk91: 🎙️ Proud to present our work from Med Onc @OffCMCVellore at #MASCC25. Interim results of “MIND & MONEY” 💭💰.Mentors: @todrashis….
0
5
0
RT @OffCMCVellore: PRAGRAD, a new patient-driven treatment approach for very advanced oral cavity #cancers (which cannot be surgically remo….
0
14
0
RT @medoncodoc: 🧪 Unresectable Oral Cavity Cancer: Radical Rx Feasible?.This observational study shows that patient choice-driven radical t….
0
4
0
RT @agingroy: 🧬 The Liquid Biopsy Truth: What $40 Billion in Cancer Screening Really Buys Us. A masterful @NewYorker investigation by @DrSi….
0
75
0
**PRAGRAD: A New Approach to Treating Very Advanced Oral Cancer** .latest from our group @cmcvelloreoff @CancerCareMASCC @oncoalert @ASCOPost @myESMO @LizzySmyth1.
0
0
2
RT @drmpk91: 🚨New meta-analysis of IC + CCRT in LA Cervical Cancer.Results Summary.📈 2-yr OS: 85% if IC ≤6wks vs 72% if >6wks.📈 2-yr OS: 84….
0
8
0
Congratulations 🎊 well deserved recognition of the work you have done over the last few years in this underrecognised but extremely important domain of cancer care. @CancerCareMASCC #ASCO25.
Grateful to @CancerCareMASCC for the #MASCC25 scholarship! 🎉.Can’t wait to share #MindAndMoney 🧠💸 study, connect with #SuppOnc champs, and focus on distress, dignity & daily life - the calm after the #ASCO25 storm of data, drama & drug approvals. #FinancialToxicity.
1
1
16
RT @airindia: There’s an #AirAboutIndia. And it’s taking over the world. Celebrate the resounding spirit of a new India - bold, joyous, an….
0
44
0
RT @dramitaol: Just responded to a medical emergency on #AirIndia flight AI504! Crew's quick response was commendable. Noted that medical….
0
139
0
What we need is a RCT looking at different local treatment modalities(hypoRT, CTRT, Sx) post induction CHEMOTHERAPY in this cohort.
ascopubs.org
PURPOSEThere is a lack of literature on treating stage III non–oncogene-driven non–small cell lung cancer (NSCLC) with low-dose immunotherapy in combination with chemotherapy for patients who are not...
Pushing the boundary of ‘borderline resectable’ NSCLC w neoadj chemoIO @JAMAOnc:. -112pt retrospective study🇮🇹🇺🇸.-T4+/-N2/3.-75% had surgery .-29% pCR 42% MPR (similar single v multistation N2) . Fuel for the tumor board🔥 @OncoAlert #LCSM
0
2
6
RT @DarwinAnil: Honored to receive the @ASCO @ConquerCancerFd IDEA Award! Grateful to @todrashish for his constant encouragement, and to @j….
0
4
0
RT @jtgeorgy: Humbled to receive the 2025 ASCO Global Oncology Young Investigator Award! Deep gratitude to @ASCO and @ConquerCancerFd for t….
0
11
0
RT @AndresFCardonaZ: This is a crucial issue that requires attention. Waiting an entire year for a response should not be acceptable, but u….
0
47
0
Ph2 trial in🇨🇳 (n=100) in unresectable stage III NSCLC: anti–PD-1 induction therapy achieved 61.7% MPR. ⚠️BST1 (AUC 0.78) identified as a predictive biomarker in PD-L1–neg/unevaluable tumors, linked to CD8+/NK infiltration and better EFS/OS (p<0.05).
0
2
9